Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%
Summary
Randomized, double-blind, parallel group, placebo-controlled, multicenter, efficacy and safety study in subjects with mild to moderate atopic dermatitis. Following the double blind period, subjects will be allowed to continue treatment with topical MRX-6 Cream 2% in an open-label extension. Demonstrate the efficacy of MRX-6 Cream 2% compared to Vehicle for the treatment of the signs and symptoms of atopic dermatitis and demonstrate the safety of MRX-6 Cream 2% for the treatment of the signs and symptoms of atopic dermatitis.
Timeline
- Start
- 2014-08
- Primary completion
- 2015-03
- Completion
- 2015-03
Outcome
Missed primary endpoint
Stopped: “Interim analysis showed lack of efficacy”
release “MRX-6 Cream Did Not Demonstrate Separation from Vehicle in Primary Endpoint of Percent Improvement in the Investigator’s Global Assessment” akaritx.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MRX-6 | Unknown | 2 % | Topical |